Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 1 de 1
1.
Ther Drug Monit ; 46(3): 281-284, 2024 Jun 01.
Article En | MEDLINE | ID: mdl-38723114

ABSTRACT: This is a case description of a patient with bipolar disorder undergoing lithium therapy who received plasmapheresis for neuromyelitis optica spectrum disorder. Plasmapheresis resulted in lower and subtherapeutic serum lithium levels. Using therapeutic drug monitoring, a dose escalation of 80% was necessary to maintain therapeutic serum lithium levels. This underscores the importance of individualized therapy through therapeutic drug monitoring.


Bipolar Disorder , Drug Monitoring , Neuromyelitis Optica , Plasmapheresis , Humans , Plasmapheresis/methods , Bipolar Disorder/therapy , Bipolar Disorder/blood , Neuromyelitis Optica/therapy , Neuromyelitis Optica/blood , Drug Monitoring/methods , Female , Lithium/blood , Lithium/therapeutic use , Intensive Care Units , Antimanic Agents/therapeutic use , Antimanic Agents/blood , Adult , Middle Aged
...